Biotechnology

XiltriX North America Announces SOC 2 Type 1 Certification for Enhanced Security and Compliance of Its Monitoring-as-a-Service Solution

October 4, 2023 8:15 AM

SAN DIEGO, CA / ACCESSWIRE / October 4, 2023 / XiltriX North America, LLC, a leading provider of real-time remote monitoring systems for the Life Science industry, is proud to announce the successful completion of its clean Service Organization Control (SOC) 2 Type 1 attestation report. This independent assessment of its internal security control demonstrates XiltriX's dedication and commitment to maintaining the highest standards of security...

Read more

Obesity Is Not an Invincible Predator - A Patented, New Approach to Cure Obesity

October 3, 2023 4:15 PM

GREENSBORO, NC and ANGUILLA, BRITISH WEST INDIES / ACCESSWIRE / October 3, 2023 / AT Research Partners is pleased to announce the issuance of US Patent #11,771,125 for a natural serotonin stimulant for appetite appeasement and weight loss, called Lactova™. Overweightness is not an invincible predator. Its causes surround us in plain sight. The epidemic is endemic to ordinary, perfectly normal biology. In cultures of abundant food and universal...

Read more

Innoveren Scientific Divests Device & Receives Capital Infusion

October 3, 2023 4:15 PM

Proceeds to be used to complete corporate rebranding, accelerate acquisition pipeline, and attract additional investment TAMPA, FL / ACCESSWIRE / October 3, 2023 / Innoveren Scientific Inc. (OTCQB:IVRN) ("Innoveren" or the "Company"), a life science company focused on becoming a leading biotech incubator, announced today that it completed the divestiture of a medical device used in spinal surgeries to a leading international medical device...

Read more

NIN/NINDS HEAL Program Grants Prestigious UH3 Award to the University of Miami, Principal Investigator Roy C. Levitt M.D, to Fund Clinical Development of Adolore BioTherapeutics’ Gene Therapy Program for the Treatment of Chronic Osteoarthritis Knee Pain

October 3, 2023 9:15 AM

UH3 Award follows the successful completion of an initial NIH/NINDS HEAL UG3 grant for which all pre-clinical milestones were met This NIH/NINDS HEAL UH3 Award will support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study in patients, undertaken in collaboration with Adolore BioTherapeutics and expected to commence in 2026 DELRAY BEACH, FL / ACCESSWIRE / October 3, 2023 / Adolore BioTherapeutics ("Adolore" or...

Read more

ZeptoMetrix Awarded in Vitro Diagnostic Regulation (IVDR) Certification

October 3, 2023 9:00 AM

BUFFALO, NY / ACCESSWIRE / October 3, 2023 / ZeptoMetrix® is pleased to announce it has been awarded an IVDR Quality Management System certificate from British Standards Institution BSI, NB 2797, one of the notified bodies under the new EU In Vitro Diagnostics Regulation (IVDR). This certificate applies to the majority of the current portfolio of CE marked ZeptoMetrix NATtrol™ quality control products that are the industry's preferred brand for...

Read more

Flightpath Biosciences and the Forsyth Institute Enter Into Co-Development Agreement Targeting Oral Disease

October 3, 2023 8:30 AM

DETROIT, MI / ACCESSWIRE / October 3, 2023 / Flightpath Biosciences, Inc. announced today that it has signed a landmark development agreement with the Forsyth Institute, a globally recognized leader in the fields of oral health research and clinical care. The development agreement contemplates a multi-indication and multi-year deal to develop new products and intellectual property, beginning with Flightpath's orally bioavailable,...

Read more

HanchorBio Announces First Patient Dosed in the Phase 1 Multi-Regional Clinical Trial of HCB101

October 3, 2023 7:30 AM

SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / October 3, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from different solid tumors or hematological malignancies with significant unmet medical needs, today announced that the first patient has been dosed in a Phase 1, multi-regional, multi-center...

Read more

Introducing the ONI Discovery Kit (TM): dSTORM in Cells

October 3, 2023 7:00 AM

Prepare for super-resolution SAN DIEGO, CA / ACCESSWIRE / October 3, 2023 / ONI is excited to introduce its latest breakthrough in super-resolution imaging solutions: the ONI Discovery Kit™ for dSTORM imaging in cells, which helps users prepare their own samples for dSTORM super-resolution microscopy with ease. Sample preparation is a critical aspect of super-resolution microscopy, and the dSTORM Discovery Kit simplifies this process by...

Read more

FluoGuide receives FDA Orphan Drug Designation for FG001 in High-Grade Glioma

October 3, 2023 4:40 AM

KØBENHAVN, DENMARK / ACCESSWIRE / October 3, 2023 / FluoGuide A/S (STO:FLUO) Orphan status applies to visualization of malignant tissue during surgery Orphan Drug Designation facilitates the development of treatment options for rare disorders Topline results of phase IIb trial in high-grade glioma expected before end-November Copenhagen, Denmark - FluoGuide A/S (OMX: FLUO "FluoGuide" or the "Company"), a pioneer in the cutting-edge field of...

Read more

Abivax Highlights Obefazimod Ulcerative Colitis Program With New Data to be Presented at the UEG Week 2023

October 2, 2023 12:20 PM

Oral presentation of Phase 2b, 96-week, open-label, maintenance efficacy and safety in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC) Moderated poster presentation highlighting correlation of pharmacokinetic (PK) parameters with enhanced expression of a single microRNA, miR-124, in blood of obefazimod-treated UC patients Poster presentation on long-term enhanced expression of miR-124 in blood and rectal...

Read more

Luventix Appoints Dr. John C. Spinosa As Medical Director Addition of Noted Pathologist to Executive Team To Direct Clinical Strategy

October 2, 2023 11:00 AM

HENDERSON, NV / ACCESSWIRE / October 2, 2023 / Luventix Inc., a development-stage company pioneering Intelligent Disease Diagnostics using Artificial Intelligence to determine the probability that a person has a disease, is pleased to announce the appointment of Dr. John C. Spinosa, M.D., Ph.D., to its executive management team. Dr. Spinosa's extensive expertise and leadership in the field of pathology make him a valuable addition to Luventix as...

Read more

M2Bio Sciences Chair, Prof Maharaj, to Deliver Keynote Address on Cutting-Edge Biotechnology Advancements

October 2, 2023 10:00 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / October 2, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update: M2Bio Sciences is delighted to announce that Professor...

Read more

EV Biologics Updates on Funding and Sales

October 2, 2023 10:00 AM

TAMPA, FL / ACCESSWIRE / October 2, 2023 / EV Biologics Corp, (OTC Pink:YECO), today announced that it has closed a $500,000 interest-free loan from a related party. This funding will provide for further development of exosome - and other nanoparticle-enriched biological products, as well as optimization of their scalable, cGMP-compatible, biomanufacturing process. The funds will be also used for comprehensive product analysis by several leading...

Read more

Abivax Files Registration Statement for Proposed Initial Public Offering in the United States

September 29, 2023 5:30 PM

PARIS, FRANCE / ACCESSWIRE / September 29, 2023 / Abivax SA (Euronext Paris:FR0012333284-ABVX)("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange...

Read more

Lexaria Announces Pricing of $1.6 Million Registered Direct Offering

September 29, 2023 8:00 AM

KELOWNA, BC / ACCESSWIRE / September 29, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to purchase 1,618,330 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering. In a concurrent private...

Read more

Seraxis to Provide Oral Update on Its Pancreatic Organoid Candidate for Functional Cure of T1D at the 59th Annual Meeting of the EASD

September 28, 2023 2:00 PM

Dr. William Rust will give an oral presentation on Seraxis' proprietary technology for the production of therapeutic pancreatic organoids from pancreas-derived stem cells, as well as review initial diabetes model data of functional cure of Type 1 Diabetes. Seraxis' presentation, entitled "Stem-cell Derived Islets for Treating Diabetes", will be delivered in the session entitled "Transplantation of Islet and Stem Cells Today and Tomorrow"....

Read more

Future Foods Invites Farmers to Register as Fermenters Now

September 28, 2023 9:00 AM

TORONTO, ON / ACCESSWIRE / September 28, 2023 / Future Foods, the innovative platform founded by serial entrepreneur Dr. Darren Burke, is calling on farmers to join hands in a mission to transform the way we grade, produce, and distribute food. As the global food landscape undergoes a significant shift towards sustainability, food waste reduction, and environmentally friendly options, Future Foods offers farmers the opportunity to be at the...

Read more

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

September 28, 2023 8:15 AM

Company's host-directed therapeutic, EB05 (paridiprubart), demonstrated a statistically significant mortality reduction among critically ill patients with severe respiratory disease TORONTO, ON / ACCESSWIRE / September 28, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced the preprint publication of favorable data from a Phase 2 substudy of...

Read more

AiCuris´ AiCubator Program Opens New Application Round for Innovative Projects with Focus on Treatment Options for Viral Infections in Immunocompromised Patients

September 28, 2023 8:15 AM

AiCuris' AiCubator program provides first-hand support for early research projects of young start-ups and academic teams that work on innovative treatment options for viral infections in immunocompromised patients. Winning projects will be awarded the AiCubator Resident Status and benefit from AiCuris' scientific know-how, its proven drug development expertise, and its extensive network in the life science industry. The fourth AiCubator...

Read more

Petros Pharmaceuticals to Present at the LD Micro Main Event XVI

September 28, 2023 8:00 AM

NEW YORK, NY / ACCESSWIRE / September 28, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the LD Micro Main Event XVI. The conference is being held on October 3 - 5, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles. Event: LD...

Read more